EMA recommends suspension of sickle cell disease medicine Oxbryta | European Medicines Agency (EMA)
Measure taken as precaution while review of emerging data is ongoing| European Medicines Agency (EMA)
Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide. Pfizer's decision is based on the totality of clinical data that now indicates the overall benefit of OXBRYTA no longer outweighs the risk in the approved sickle cell patient populati...| www.pfizer.com
Measure taken as precaution while review of emerging data is ongoing| European Medicines Agency (EMA)
Please provide your information and your questions below. We will contact you the same day. If you need immediate help, call 800-553-8082. We are available 24 hours a day.| Lawsuit Information Center
